Table 4.
Pharmacological Variables of AP-LAI Treatments
| Variables | Patients Treated with HAL-D (n=34) | Patients Treated with PP1M (n=17) | Patients Treated with PP3M (n=22) | Total (n=73) | Statistical Test. Probability |
|---|---|---|---|---|---|
| DURATION OF TREATMENT, m±SD | |||||
| Days of therapy | 1232.93±431.29 | 940.35±392.66 | 631.60±90.71 | 972.88±432.33 | ANOVA F=19.06 |
| p=0.000 | |||||
| MOTIVATIONS FOR LAI PRESCRIPTION, n (%) | |||||
| Lack of therapeutic adherence | 33 (97.1%) | 15 (88.2%) | 17 (77.3%) | 65 (89%) | Test χ2NS |
| Patient’s choice | 1 (2.9%) | 2 (11.8%) | 2 (9.1%) | 5 (7%) | |
| Unsatisfactory clinical response | 0 | 0 | 2 (9.1%) | 2 (3%) | |
| Intolerance to other drugs | 0 | 0 | 1 (4.5%) | 1 (1%) | |
| FREQUENCY OF ADMINISTRATION, m±SD | |||||
| Days | 25.56±6.14 | 29.35±3.04 | 87.27±4.56 | 45.04±28.42 | ANOVA F=1078.09 p=0.0000 |
| POSOLOGY (mg) | |||||
| Mean±SD | 112.5±54.79 | 85.29±36.51 | 293.27±130.61 | - | - |
| Median (min-max) | 100 (25–225) | 75 (50–150) | 263 (175–525) | - | - |
| SIDE EFFECTS, n (%) | |||||
| Patients with side effects during 1-year AP-LAI treatments | 6 (17.6%) | 15 (88.2%) | 15 (68.2%) | 36 (49.3%) | Pearson |
| χ2 =14.83 | |||||
| p=0.001 | |||||
| ASSOCIATED ORAL PSYCHOPHARMACOLOGICAL THERAPY, n (%) | |||||
| Patients with associated oral therapy at 6-month AP-LAI | 30 (85.7%) | 13 (50%) | 17 (65.4%) | 60 (69%) | Pearson |
| χ2 = 9.11 | |||||
| p=0.011 | |||||
| Patients with associated oral therapy at 12-month AP-LAI | 29 (85.3%) | 7 (41.2%) | 11 (50%) | 47 (64%) | Pearson |
| χ2 = 12.46 | |||||
| p=0.002 | |||||
Note: NS=Not Significant.